purpos
commun
transmiss
detect
spain
februari
intens
care
unit
icu
capac
expand
vitoria
march
th
identifi
patient
two
public
hospit
vitoria
admit
icu
confirm
infect
data
report
avail
march
mortal
assess
complet
icu
stay
identifi
patient
male
confirm
median
interquartil
rang
iqr
age
patient
year
symptom
began
median
day
icu
admiss
common
comorbid
identifi
obes
n
arteri
hypertens
n
chronic
lung
diseas
n
patient
admit
hypoxem
respiratori
failur
none
receiv
noninvas
mechan
ventil
fortyf
underw
intub
hfnt
extracorpor
membran
oxygen
ecmo
requir
prone
posit
day
intub
patient
die
within
one
week
extub
underw
mechan
ventil
six
patient
document
coinfect
procalcitonin
plasma
associ
vs
p
risk
death
day
conclus
earli
experi
spain
suggest
strategi
right
oxygen
avoid
noninvas
mechan
ventil
lifesav
sevenday
mortal
requir
intub
lower
patient
still
requir
mechan
ventil
day
icu
admiss
half
patient
remain
intub
wherea
one
third
die
sinc
initi
identif
infect
wuhan
import
identifi
characterist
beyond
china
implic
manag
report
describ
icu
patient
china
still
limit
clinic
cours
adult
inpati
wuhan
report
high
mortal
rate
risk
death
presenc
high
ngml
procalcitonin
pct
plasma
patient
china
itali
receiv
noninvas
ventil
inform
need
patient
follow
strategi
earli
intub
without
induc
potenti
ventilatorinduc
lung
injuri
moreov
view
limit
resourc
also
import
improv
insight
mortal
identifi
differ
phenotyp
personalis
manag
capit
alava
citi
basqu
countri
experienc
acceler
curv
spanish
provinc
relat
massiv
contagion
funer
icu
capac
alreadi
wuhan
usa
mortal
report
wuhan
suggest
close
associ
assess
correl
plasma
procalcitonin
icu
admiss
mortal
j
u
r
n
l
p
r
e
p
r
f
consecut
adult
patient
year
old
univers
hospit
araba
vitoria
spain
march
march
th
includ
patient
requir
hospitalis
diagnosi
accord
interim
guidanc
includ
patient
follow
icu
discharg
death
march
first
patient
admiss
march
clinic
data
collect
prospect
investig
pct
plasma
level
sampl
obtain
within
icu
admiss
noninvas
ventil
indic
cohort
intub
clinic
indic
presenc
respiratori
alkalosi
progress
hyperventil
deliv
high
oxygen
concentr
basic
epidemiolog
clinic
laboratori
microbiolog
treatment
outcom
data
extract
hb
standardis
crf
modifi
isar
crf
studi
protocol
approv
irb
inform
consent
waiv
ref
patient
data
censor
day
follow
april
surviv
data
estim
icu
admiss
clinic
specimen
identif
obtain
accord
centr
diseas
control
guidelin
method
laboratori
confirm
pcr
perform
hospit
laboratori
page
j
u
r
n
l
p
r
e
p
r
f
confirm
case
defin
posit
result
reversetranscriptasechainreact
rtpcr
assay
nasopharyng
swab
respiratori
specimen
comorbid
identifi
hospit
chart
definit
use
articl
report
elsewher
procalcitonin
plasma
level
determin
assay
alin
abbott
eeuu
assay
detect
limit
ngml
probabl
sensit
upperreferencerang
healthi
subject
determin
pct
plasma
level
perform
within
hour
icu
admiss
consid
rapid
spread
pandem
aim
studi
report
fast
overview
situat
one
first
citi
impact
outbreak
therefor
sampl
size
calcul
continu
variabl
describ
median
interquartil
rang
iqr
mean
standard
deviat
sd
categor
variabl
present
count
percentag
pairwis
comparison
categor
variabl
perform
use
pearson
test
comparison
continu
variabl
use
student
ttest
mannwhitney
test
accord
distribut
statist
signific
consid
pvalu
less
statist
analys
perform
spss
statist
version
softwar
ibm
associ
surviv
pct
plasma
level
estim
use
kaplanmei
curv
hazard
ratio
hr
confid
interv
ci
comput
use
long
rank
test
statist
signific
consid
pvalu
less
statist
analys
perform
graphpad
prism
softwar
common
symptom
icu
admiss
fever
dyspnoea
cough
malais
myalgia
uncommon
ninetyfour
percent
patient
receiv
antivir
treatment
lopinavirritonavir
hydroxychloroquin
plu
interferon
beta
empir
antibiot
agent
administr
patient
wherea
coinfect
identifi
patient
chestx
ray
find
report
tabl
studi
describ
critic
ill
patient
covid
sever
acut
respiratori
failur
vitoria
spain
march
march
patient
receiv
hfnt
intub
noninvas
mechan
ventil
appli
two
week
icu
admiss
three
ten
intub
patient
die
half
patient
cohort
requir
prolong
ventilatori
support
two
ten
intub
patient
extub
discharg
second
week
ventil
plasma
procalcitonin
threshold
fail
predict
mortal
find
suggest
oxygen
strategi
emphasis
optimis
oxygen
intub
base
clinic
criteria
hyperventil
avoid
ventilatorinduc
lung
injuri
associ
noninvas
mechan
ventil
would
lifesav
signific
proport
patient
tabl
compar
current
find
first
seri
icu
china
usa
pandem
influenza
spain
clinic
present
consist
recent
systemat
review
lymphocytopenia
coagul
alter
common
hospit
admiss
import
differ
document
compar
pandem
influenza
tabl
report
elsewher
also
first
icu
seri
report
wuhan
obes
common
comorbid
report
suggest
differ
western
countri
regard
wuhan
report
follow
hypertens
chronic
respiratori
j
u
r
n
l
p
r
e
p
r
f
diseas
low
preval
immunocompromis
solid
organ
transplant
hiv
pregnant
patient
compar
sever
influenzainfect
patient
may
associ
interact
coronaviru
innat
immun
fei
zhou
et
al
report
risk
death
patient
high
procalcitonin
consist
find
due
differ
laboratori
techniqu
coinfect
rate
degre
acut
lung
injuri
niv
appli
cohort
although
inform
procalcitonin
requir
find
suggest
prognost
inform
infer
earli
report
characterist
influenza
spain
interest
inform
current
avail
come
larg
cohort
china
short
case
seri
itali
usa
import
characterist
current
cohort
patient
expos
prior
noninvas
ventil
commonli
perform
use
facial
mask
wuhan
helmet
itali
protocol
earlier
intub
base
hyperventil
unabl
maintain
patient
cohort
intub
median
day
onset
later
pandem
influenza
earlier
day
although
mortal
avail
due
earli
report
mortal
estim
lower
cohort
patient
extub
within
second
week
mean
prognosi
better
differ
strategi
oxygen
contrast
report
china
seattl
suggest
sever
ard
strategi
earli
intub
disclos
lead
typic
ard
experi
two
third
patient
initi
lung
complianc
mlcm
postintub
consist
preliminari
report
patient
gattinoni
et
al
suggest
ard
consequ
acut
lung
injuri
associ
delay
intub
superinfect
thu
noninvas
ventil
seem
recommend
earli
high
peep
cm
probabl
right
ventilatori
strategi
may
harm
experi
suggest
avoid
spontan
ventil
earli
ed
ward
may
harm
thu
patient
maintain
highflow
oxygen
nasal
therapi
hfnt
highconcentr
oxygen
reservoir
present
extrem
hyperventil
earli
diseas
nonintub
patient
may
benefit
prone
posit
intub
three
patient
manag
like
without
intub
discharg
earli
recruit
manoeuvr
contraind
benefit
prone
posit
intub
patient
protect
ventil
restrict
develop
acut
lung
injuri
find
suggest
hypoxem
vasoconstrict
main
earli
mechan
patient
benefit
inhal
prostacyclin
nitric
oxid
develop
tachyphylaxi
lastli
although
document
pulmonari
embol
cohort
autopsi
allow
laboratori
test
consist
endotheli
injuri
microthrombosi
zhou
et
al
report
serum
ferritin
median
ngl
among
nonsurvivor
context
hyperinflammatori
state
patient
receiv
measur
bone
marrow
aspir
rule
system
haemophagocyt
lymphocytosi
treat
mgkg
gamma
globulinsday
dexamethason
h
day
author
also
report
ddimer
ugml
among
nonsurvivor
j
u
r
n
l
p
r
e
p
r
f
find
consist
observ
although
differ
overal
mortal
found
heparin
user
nonus
vs
p
report
among
patient
sever
infect
china
mortal
significantli
reduc
receiv
low
molecular
weight
heparin
ddimer
fold
upper
limit
normal
vs
p
sic
score
vs
p
studi
sever
limit
half
cohort
remain
icu
time
censor
april
th
outcom
assess
perform
sampl
size
small
focus
critic
ill
data
extrapol
patient
hospitalis
medic
ward
howev
earli
report
illustr
epidemiolog
south
europ
compar
wuhan
initi
report
pandem
influenza
spain
tabl
alreadi
expand
icu
capac
twofold
march
th
data
generalis
patient
anoth
acceler
phase
differ
avail
resourc
may
serv
develop
conting
plan
geograph
region
procalcitonin
techniqu
determin
may
influenc
valu
data
may
compar
use
method
determin
plasma
valu
similarli
strategi
earli
intub
without
prior
noninvas
ventil
trial
would
mean
data
extrapol
site
manag
strategi
lastli
pulmonari
complianc
drive
pressur
record
studi
protocol
limit
identif
phenotyp
extrapol
site
earli
experi
spain
suggest
right
oxygen
lifesav
sevenday
mortal
requir
intub
lower
patient
still
requir
prolong
mechan
ventil
pct
plasma
level
predict
surviv
day
icu
admiss
half
patient
remain
intub
wherea
one
third
nonsurvivor
clinic
observ
provid
use
insight
help
improv
manag
outcom
author
declar
conflict
interest
regard
manuscript
work
fund
part
ciber
instituto
salud
carlo
iii
madrid
spain
fondo
feder
studi
approv
clinic
research
ethic
committe
araba
hospit
consent
waiv
due
observ
natur
studi
applic
dataset
gener
andor
analys
current
studi
publicli
avail
due
privaci
patient
data
avail
correspond
author
reason
request
studi
design
jr
hb
enrol
patient
respons
integr
data
analysi
data
perform
st
hb
jm
jr
st
wrote
first
draft
manuscript
author
contribut
scientif
subsequ
version
author
read
approv
final
manuscript
pseudomona
